What is HC Wainwright’s Estimate for AMLX Q1 Earnings?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) – Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Amylyx Pharmaceuticals in a report issued on Wednesday, March 5th. HC Wainwright analyst A. Fein expects that the company will post earnings of ($0.43) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Amylyx Pharmaceuticals’ current full-year earnings is ($2.20) per share. HC Wainwright also issued estimates for Amylyx Pharmaceuticals’ Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.43) EPS and FY2029 earnings at $0.07 EPS.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.06). The business had revenue of ($0.67) million during the quarter.

Other equities analysts have also issued reports about the company. Baird R W raised Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Monday, November 18th. Robert W. Baird upgraded Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $3.00 to $11.00 in a research report on Monday, November 18th. Five analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Amylyx Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $7.33.

Amylyx Pharmaceuticals Stock Up 7.2 %

AMLX stock opened at $3.87 on Friday. The firm has a market cap of $265.28 million, a PE ratio of -1.01 and a beta of -0.51. The business has a 50 day moving average of $3.53 and a 200-day moving average of $3.87. Amylyx Pharmaceuticals has a 12-month low of $1.58 and a 12-month high of $7.27.

Insider Activity at Amylyx Pharmaceuticals

In other news, CEO Joshua B. Cohen sold 11,851 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $3.47, for a total transaction of $41,122.97. Following the transaction, the chief executive officer now directly owns 3,201,247 shares of the company’s stock, valued at approximately $11,108,327.09. This trade represents a 0.37 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Justin B. Klee sold 7,471 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $4.04, for a total value of $30,182.84. Following the transaction, the chief executive officer now directly owns 3,176,788 shares in the company, valued at $12,834,223.52. This trade represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 27,169 shares of company stock valued at $97,274 over the last 90 days. 11.70% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Blue Trust Inc. grew its stake in shares of Amylyx Pharmaceuticals by 232.1% during the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after buying an additional 4,883 shares during the last quarter. XTX Topco Ltd grew its stake in shares of Amylyx Pharmaceuticals by 12.0% during the fourth quarter. XTX Topco Ltd now owns 53,376 shares of the company’s stock valued at $202,000 after buying an additional 5,704 shares during the last quarter. Northern Trust Corp grew its stake in shares of Amylyx Pharmaceuticals by 11.8% during the fourth quarter. Northern Trust Corp now owns 106,564 shares of the company’s stock valued at $403,000 after buying an additional 11,214 shares during the last quarter. Fox Run Management L.L.C. bought a new position in shares of Amylyx Pharmaceuticals during the fourth quarter valued at about $45,000. Finally, Alpine Global Management LLC bought a new position in shares of Amylyx Pharmaceuticals during the fourth quarter valued at about $45,000. 95.84% of the stock is owned by institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.